within Pharmacolibrary.Drugs.ATC.R;

model R05DB29
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.78,
    Cl             = 0.08833333333333333,
    adminDuration  = 600,
    adminMass      = 0.05,
    adminCount     = 1,
    Vd             = 0.111,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Gefapixant is a selective P2X3 receptor antagonist used for the treatment of refractory or unexplained chronic cough in adults. It is an orally administered small molecule. Gefapixant received approval for this indication in several regions including the United States and Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers. Parameter values are population estimates following single oral dosing.</p><h4>References</h4><ol><li>Jesse C Nussbaum, Azher Hussain, Peter Butera, Anthony P Ford, Michael M Kitt, Edward A O'Neill, Steven Smith, Gabriel Vargas, Terry O'Reilly, Chris Wynne, S Aubrey Stoch, Marian Iwamoto,Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults.,Journal of clinical pharmacology,2024<a href='https://pubmed.ncbi.nlm.nih.gov/38651193/'>https://pubmed.ncbi.nlm.nih.gov/38651193/</a></li><li>Jesse C Nussbaum, Azher Hussain, K Chris Min, Thomas C Marbury, Kenneth Lasseter, S Aubrey Stoch, Marian Iwamoto,Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.,Journal of clinical pharmacology,2022<a href='https://pubmed.ncbi.nlm.nih.gov/35656754/'>https://pubmed.ncbi.nlm.nih.gov/35656754/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R05DB29;
